BioCentury on BioBusiness,
Product Discovery & Development
Table: PI3K deal flow
Back to the parent article
Monday, February 27, 2012
At least nine deals primarily focusing on compounds
that inhibit phosphoinositide 3-kinase (PI3K) and/or its isoforms were
completed over the past seven years for more than $3 billion, including
milestones. Of the deals with upfront figures disclosed, the largest payment
($375 million) went to the acquisition of Calistoga Pharmaceuticals Inc. by Gilead
Sciences Inc. (NASDAQ:GILD). Intellikine Inc. received the second
largest up front ($190 million) from its acquisition by Takeda Pharmaceutical
Co. Ltd. (Tokyo:4502). Source: BCIQ: BioCentury Online Intelligence
PI3K assets (product status at time of deal)
Takeda Pharmaceutical Co. Ltd. (Tokyo:4502)
INK1117, a PI3K alpha inhibitor
in Ph I for solid tumors; IPI-145, a PI3K delta/gamma inhibitor in Ph I for
hematological malignancies, licensed to Infinity Pharmaceuticals Inc. (NASDAQ:INFI)
in 2010; and INK128, an mTOR complex 1 (mTORC1)/ mTORC2 inhibitor in Ph I for
multiple myeloma (MM) and solid tumors; plus large library of pre- clinical
compounds against thePI3K/mTOR pathway and other kinases
$190M up front; up to $120M in
Dec-2011 (closed Jan-2012)
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2013 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
If you are a current subscriber, log in below or in the upper right corner of this
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]